Cordyceps Sunshine Biotech Holdings (RAJAF) Cash & Equivalents (2020 - 2025)

Cordyceps Sunshine Biotech Holdings' Cash & Equivalents history runs 6 years deep, the most recent figure standing at $3199.0 for Q4 2025.

• In Q4 2025, Cash & Equivalents fell 91.42% year-over-year to $3199.0; the TTM figure through Dec 2025 stood at $3199.0 (down 91.42% YoY), while the FY2025 annual figure was $3199.0, down 91.42% from the prior year.
• Cash & Equivalents was $3199.0 for Q4 2025 at Cordyceps Sunshine Biotech Holdings, down from $37284.0 in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $99684.0 in Q4 2021 to a low of $3199.0 in Q4 2025.
• Historically, Cash & Equivalents has averaged $31145.5 across 5 years, with a median of $20039.0 in 2023.
• The sharpest annual moves came in 2021 and 2022: Cash & Equivalents surged 33806.12% in 2021, then sank 93.35% in 2022.
• A 5-year view of Cash & Equivalents shows it stood at $99684.0 in 2021, then tumbled by 93.35% to $6628.0 in 2022, then jumped by 248.58% to $23104.0 in 2023, then surged by 61.37% to $37284.0 in 2024, then slumped by 91.42% to $3199.0 in 2025.
• The last three Cash & Equivalents figures came in at $3199.0 (Q4 2025), $37284.0 (Q4 2024), and $23104.0 (Q4 2023), per Business Quant data.